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Abstract
OBJECTIVE: To observe the efficacy of a traditional
Chinese medicine, Shenzhuo formula, on patients
with diabetic kidney disease (DKD).
METHODS: Eighty-eight outpatients with DKD
were enrolled. Changes in estimated glomerular fil-
tration rate (eGFR), creatinine clearance, serum cre-
atinine, blood-urea-nitrogen, albuminuria, glycosyl-
ated hemoglobin (HbA1C), blood pressure, and lipid
profile were measured and analyzed before and af-
ter intervention with Shenzhuo formula for 1, 3, 6,
9, 12, and 18 months.
RESULTS: Compared with the baseline amounts, se-
rum creatinine decreased, and eGFR and creatinine
clearance increased, significantly after intervention
for 1, 3, 6, 9, 12, and 18 months (all P < 0.05). Mean
eGFR increased by 2.11 mL/min per 1.73 m2/y after
18-month treatment. Urinary protein at 24 h de-
creased significantly after 1, 3, 9, and 12 months
(P < 0.05). HbA1C decreased significantly (P < 0.05) af-
ter 3, 6, 9, 12, and 18 months, and systolic blood
pressure decreased significantly (P < 0.05) after 1, 3,
and 6 months. Total cholesterol decreased signifi-
cantly (P < 0.05) after 1, 3, 6, and 18 months. Triglyc-
eride and low-density lipoprotein-cholesterol de-
creased significantly (P < 0.05) after 1 and 3 months.
CONCLUSION: Shenzhuo formula can improve eG-
FR and possibly slow DKD progression. Shenzhuo
formula can also lower HbA1C, lipid levels and blood
pressure.
© 2015 JTCM. All rights reserved.
Key words: Diabetic nephropathies; Creatinine; Es-
timatedglomerular filtrationrate;Shenzhuoformula
INTRODUCTION
Diabetic kidney disease (DKD) is one of the most se­
vere complications of diabetes mellitus (DM). The
prevalence of DKD is increasing gradually because
more people are suffering from DM. DKD is the pri­
mary cause of end­stage renal disease. The high inci­
dence of DM and DKD results in considerable bur­
dens upon medical resources and society. Thus, a num­
ber of DM­ and DKD­preventative therapies have
been advocated.1­3
According to international guidelines on DKD,1 man­
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aging indices such as serum creatinine (Scr), creatinine
clearance (Ccr), and, albuminuria can postpone PKD
progression. In fact, most DKD patients cannot
achieve these goals. Thus, it is important to search for
new candidate drugs for DKD for such patients.
Researchers have demonstrated the clinical benefit of
tight glycemic control, which can prevent/postpone di­
abetic complications.4 Because DKD patients usually
have the complications of hypertension and dyslipid­
emia, optimal treatment involves controlling blood
pressure (BP) and lipids. Such combined therapy can
decrease the risk of cardiovascular events and aid kid­
ney function.5­7
This retrospective analysis focused on DKD patients
administered a traditional Chinese medicine, namely,
Shenzhuo formula [Dahuang (Radix Et Rhizoma Rhei
Palmati), Shuizhi (Hirudo), Huangqi (Radix Astragali
Mongolici), Danshen (Radix Salviae Miltiorrhizae)]. We
assessed the effects of Shenzhuo formula on kidney
function, estimated glomerular filtration rate (eGFR),
BP, and lipid profiles.
MATERIALS ANDMETHODS
General data
Subjects were outpatients from the Endocrine Depart­
ment of Guang'anmen Hospital, China Academy of
Chinese Medical Sciences (Beijing, China) from July
2007 to July 2012.
Diagnosis
A total of 88 subjects were enrolled for screening. Diag­
nostic criteria for DM was based on those set by the
World Health Organization in 1999.8 Diagnostic crite­
ria for DKD were based on Clinical Practice Guide­
lines and Clinical Practice Recommendations for Dia­
betes and Chronic Kidney Disease set by the American
Kidney Foundation in 2007.1 These criteria were Scr >
106 μmol/L or Ccr < 80 mL/min or eGFR <90 mL/
min per 1.73 m2 or urinary protein of 300­3500/24 h.
Diagnostic criteria for hypertension were based on
guidelines for the prevention and treatment of hyper­
tension in 2010 by Chinese and American organiza­
tions.9,10 Diagnostic criteria for dyslipidemia were based
on guidelines for the prevention and management of
dyslipidemia set by the China Joint Commission
2007.11
Inclusion criteria
Subjects were included in the study if they met the di­
agnostic criteria described above and if they underwent
examinations in Guang'anmen Hospital. The fol­
low­up period was > 3 months and the Scr test was
conducted more than twice.
Exclusion criteria
Patients in whom urinary levels of protein were caused
by primary nephritis, who had drug­induced renal
damage, or other secondary nephropathies were exclud­
ed. Patients were excluded if they had: diabetic ketoaci­
dosis or severe inflammation within the previous
month; complications of severe cardiovascular / cere­
brovascular diseases; diseases of the liver or hematopoi­
etic system; or mental illness. Women who were preg­
nant, planning to become pregnant, or who were
breastfeeding could not participate in this study. Pa­
tients were also excluded if they: had allergies (or a his­
tory of allergies); were consuming alcohol and/or psy­
choactive substances; or participating in other clinical
trials.
Intervention
DKD patients' levels of blood glucose, lipid, and BP
were stabilized by oral medications or insulin injec­
tions. All patients were administered a modified Shen­
zhuo formula (200 mL, b.d.). Shenzhuo formula was
taken 30 min before or after breakfast and supper.
Treatment lasted ≥ 12 weeks.
Measurements
Measurements of Scr, blood­urea­nitrogen (BUN),
24­h urinary protein, glycosylated hemoglobin (HbA­
IC) and lipids were carried out in a central laboratory
in Guang'anmen Hospital after an overnight fast of
10­12 h. BP was taken (on the non­dominant arm,
supported at heart level) by a physician. Levels of Scr
and BUN were measured using an enzymatic method
(UniCel DxC 800 Automatic Biochemical Analyzer;
Beckman Coulter, Fullerton, CA, USA). Urinary levels
of protein over 24 h were measured using the Pyrogal­
lol Red method (Synchron Automatic Biochemical An­
alyzer; Beckman Coulter). HbA1c levels were measured
by an enzymatic method (7020 Automatic Biochemi­
cal Analyzer; Hitachi, Tokyo, Japan). Levels of total
cholesterol (TC) and triglycerides (TG) were measured
by enzymatic methods (Beckman Coulter). Levels of
high­density lipoprotein cholesterol (HDL­C) and
low­density lipoprotein cholesterol (LDL­C) were de­
termined by immuno­inhibition methods (HDL­C,
LDL­C Direct; Wako Pure Chemical Industries, Osa­
ka, Japan).
Measurements of Scr, BUN, 24­h urinary protein,
HbA1C, BP, and lipid profile for each patient were re­
corded at the first visit and 1, 3, 6, 9, 12, and 18
months after the first visit. eGFR, Ccr, and reciprocal
serum creatinine (rScr) were calculated by Modifica­
tion of Diet in Renal Disease formula. Adverse
events were assessed using vital signs, clinical signs and
symptoms.12­15
Statistical analyses
Statistical analyses were processed via SPSS v15.0
(IBM, Armonk, NY, USA). Measurement data were
the mean ± standard deviation ( xˉ ± s). The paired
t­test was used to compare baseline and after­interven­
tion changes in the abovementioned characteristics. A
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two­sample comparison of means was conducted by
the independent samples t­test. Disaggregated data cor­
relation was conducted by the χ2 test. P < 0.05 was con­
sidered significant.
RESULTS
General characteristics
This retrospective study involved 88 patients, the base­
line characteristics of which are shown in Table 1. In to­
tal, 73 patients suffered from hypertension and 64 suf­
fered from dyslipidemia.
Indices of kidney function
Compared with the baseline (paired t­test), mean eG­
FR increased by 5.45, 7.66, 8.67, 9.84, and 9.93 mL/
min per 1.73 m2 after intervention for 1, 3, 6, 9, and
12 months, respectively. Mean Ccr increased by 4.86,
7.06, 8.00, 9.49, 9.50, and 9.91 mL/min, and mean
Scr decreased by 7.48, 11.81, 16.65, 15.23, 14.50, and
17.76 μmol/L after 1, 3, 6, 9, 12, and 18 months, re­
spectively. Mean 24­h urinary protein decreased by
136.93, 195.84, 231.58, and 311.81 mg/24 h after in­
tervention for 1, 3, 9, and 12 months, respectively. All
the results mentioned above exhibited significant differ­
ences (P < 0.05) (Table 2, Table 3).
HbA1C, BP, and lipids
Compared with baseline (paired t­test), after interven­
tion for 3, 6, 9, 12, and 18 months, mean HbA1C de­
creased by 0.39, 0.36, 0.56, 0.59, and 0.63%, respec­
tively.MeanBPdecreasedby4.67,5.60,and7.21 mm Hg
after 1, 3, and 6 months, respectively. Mean TC de­
creased by 0.30, 0.51, 0.66, and 0.52 mmol/L after 1,
3, 6, and 18 months, respectively. Mean TG decreased
by 0.34 and 0.54 mmol/L after 1 and 3 months, respec­
tively. Mean LDL­C decreased by 0.33 mmol/L after
3 months. All the changes mentioned above were sig­
nificant (P < 0.05) (Table 4).
Kidney function and relevant indices
We found that 64 out of 88 DKD patients had im­
proved/non­worsened kidney function and relevant in­
dices, whereas 24 patients had worse kidney function
and relevant indices. We analyzed the general data and
found that those patients whose kidney function wors­
ened had a longer duration and a younger age at diag­
Parameter
Age (years)
Male sex (n)
Known duration of DM (years)
Known duration of nephropathy (years)
Age at diagnosis of DM (years)
Age at diagnosis of nephropathy (years)
Known duration of follow­up (years)
Glucose­lowering treatment
Dyslipidemia
Blood pressure
Oral hypoglycemic agents (n)
Insulin (n)
eGFR (mL/min)
Ccr (mL/min)
Scr (μmmol)
BUN (mmol/L)
Albuminuria (mg)
HbA1C (%)
TC (mmol/L)
TG (mmol/L)
HDL­C (mmol/L)
LDL­C (mmol/L)
SBP (mm Hg)
DBP (mm Hg)
Mean (standard deviation) (range) or n (%)
57.79 (13.59) (22­89)
56 (63.78)
11.64 (7.30) (1­40)
3.22 (2.85) (1­15)
47.14 (13.77) (17­76)
55.71 (13.50) (26­77)
13.69 (10.67) (1­48)
42 (47.72)
63 (71.59)
41.76 (14.65) (6.77­67.36)
43.65 (17.28) (8.57­88.31)
169.98 (87.95) (108­575.4)
11.48 (3.20) (4.17­24.41)
1066.79 (849.46) (300.2­3440.00)
7.41 (1.30) (5.2­10.8)
6.44 (1.47) (4.21­12.31)
2.78 (1.39) (1.59­9.60)
1.06 (0.23) (0.62­1.79)
4.48 (0.78) (3.40­6.57)
141.90 (19.73) (105­190)
80.59 (12.44) (60­110)
Notes: DKD: diabetic kidney disease; eGFR: estimated glomerular filtration rate; DM: diabetes mellitus; Ccr: creatinine clearance; Scr: se­
rum creatinine; BUN: blood­urea­nitrogen; HbA1C: glycosylated hemoglobin; TC: total cholesterol; TG: triglyceride; HDL­C: high­density
lipoprotein­cholesterol; LDL­C: low­density lipoprotein cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure.
Table 1 Baseline of patients with DKD
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Table 2 Variations in kidney function in patients with DKD after intervention ( xˉ ± s)
Variable
Scr (μmol/L)
GFR (mL/min per 1.73 m2)
Ccr (mL/min)
Albuminuria (mg/24 h)
BUN (mmol/L)
Intervention period (months)
1
3
6
9
12
18
1
3
6
9
12
18
1
3
6
9
12
18
1
3
6
9
12
18
1
3
6
9
12
18
n
88
57
51
36
32
16
88
57
51
36
32
16
88
57
51
36
32
16
71
43
39
34
28
13
85
55
41
34
29
17
Baseline
170.0±88.0
167.8±84.6
159.9±76.2
156.0±55.3
153.3±52.5
140.8±25.0
41.8±14.7
42.5±14.1
42.3±13.1
42.5±13.9
43.7±13.3
44.4±12.5
43.7±17.3
44.2±16.8
43.6±15.7
44.8±16.4
46.1±16.3
46.9±14.9
1066.8±849.5
1153.0±883.1
1215.1±933.9
1229.5±864.5
1326.8±914.5
1462.8±883.6
11.5±3.2
11.8±3.6
11.4±3.1
11.7±3.2
11.5±3.0
10.9±2.4
Intervention
162.6±97.1
156.0±94.6
143.4±78.3
141.6±69.0
138.8±71.2
123.1±32.9
47.2±20.4
50.2±21.5
51.0±19.0
52.3±22.4
53.6±21.9
54.7±23.9
48.5±22.4
51.3±24.5
51.6±21.9
54.3±25.9
55.6±25.8
56.8±25.0
929.9±844.9
957.1±906.7
1064.7±1108.4
997.9±841.3
1014.9±996.6
1083.1±887.6
11.3±4.0
11.2±4.4
10.8±4.4
10.5±4.1
10.5±4.0
14.0±4.5
t value
–2.52
–3.01
–3.62
–2.30
–2.22
–2.37
5.00
4.53
5.15
4.16
3.40
2.10
4.98
4.46
5.12
4.14
3.36
2.22
–2.24
–2.30
–1.56
–2.48
–2.63
–1.94
–0.58
–1.65
–1.15
–2.03
–1.62
0.67
P value
0.01a
0.00b
0.00b
0.03a
0.03a
0.03a
0.00b
0.00b
0.00b
0.00b
0.00b
0.05
0.00b
0.00b
0.00b
0.00b
0.00b
0.04a
0.03a
0.03a
0.13
0.02a
0.01a
0.08
0.56
0.10
0.26
0.05
0.12
0.51
Notes: all patients took a modified Shenzhuo formula (200 mL, b.d.). Shenzhuo formula was taken 30 min before or after breakfast and
supper. Scr: serum creatinine; eGFR: estimated glomerular filtration rate; Ccr: creatinine clearance; BUN: blood­urea­nitrogen. Compared
with baseline, aP < 0.05, bP < 0.01.
Intervention period (months)
1
3
6
9
12
18
n
88
57
51
36
32
16
Rate of GFR decrease (mL/min per 1.73 m2/y)
5.44
2.8
1.53
1.17
0.98
0.72
Slope of reciprocal Scr (×106L·μmol–1·d–1)
6.07
5.04
2.85
4.26
5.96
6.02
Notes: all patients took a modified Shenzhuo formula (200 mL, b.d.). Shenzhuo formula was taken 30 min before or after breakfast and
supper. Scr: serum creatinine; eGFR: estimated glomerular filtration rate; Ccr: creatinine clearance.
Table 3 Rate of decrease in estimated glomerular filtration rate and slope of reciprocal serum creatinine in patients with DKD after
intervention ( xˉ ± s)
531
JTCM |www. journaltcm. com October 15, 2015 |Volume 35 | Issue 5 |
Tian JX et al. / Clinical Study
nosis for DM and DKD than those whose kidney func­
tion improved/did not worsen. DM course was (12.49
± 6.34) versus (11.61 ± 8.63) years, respectively.The diag­
nostic age of DM and DKD was (48 ± 13) versus (47
± 13) and (58 ± 12) versus (53 ± 15) years, respectively.
The relationships among kidney function, age, course
of DM, and age at diagnosis is shown in Figure 1.
Scr, lipids, and BP at first visit tended to be higher in
patients whose kidney function worsened than in those
in which it improved/did not worsen after interven­
Variable
HbA1C (%)
SBP (mm Hg)
DBP (mm Hg)
TC (mmol/L)
TG (mmol/L)
HDL­C (mmol/L)
LDL­C (mmol/L)
Intervention period (months)
3
6
9
12
18
1
3
6
12
18
1
3
6
12
18
1
3
6
12
18
1
3
6
12
18
1
3
6
12
18
1
3
6
12
18
n
73
40
30
26
23
86
53
48
28
14
86
53
48
28
14
70
40
25
22
15
70
40
25
22
15
45
32
18
13
12
61
33
19
18
13
Baseline
7.41±1.30
7.35±1.09
7.54±1.14
7.36±1.15
7.64±1.26
141.90±19.73
143.56±20.76
142.35±18.97
143.67±19.53
143.07±25.11
80.59±12.44
80.73±12.21
81.68±14.10
81.07±13.63
80.00±14.14
6.44±1.47
6.51±1.61
6.74±1.56
6.57±1.63
6.63±0.89
2.78±1.39
2.90±1.34
3.20±1.88
3.43±2.01
3.28±1.66
1.06±0.23
1.03±0.23
0.99±0.17
0.97±0.19
0.99±0.21
4.48±0.78
4.24±0.62
4.34±0.79
4.20±0.67
4.24±0.51
Intervention
7.03±1.17
7.00±1.03
6.99±1.12
6.78±1.01
7.01±1.48
136.42±17.88
137.96±15.69
135.15±18.90
139.07±19.53
134.00±14.73
78.22±10.09
78.32±11.95
78.56±10.96
76.96±9.26
76.79±8.46
6.13±1.52
6.00±1.52
6.09±1.33
6.05±1.85
6.11±1.12
2.44±1.14
2.36±0.97
2.87±2.13
3.01±1.67
2.85±1.53
1.15±0.30
1.13±0.26
1.03±0.21
1.06±0.14
1.07±0.18
4.35±0.96
3.91±0.77
4.08±1.13
4.02±1.05
4.17±0.87
t value
–2.67
–2.19
–2.53
–2.67
–2.35
–2.28
–2.56
–2.25
–1.17
–1.40
–1.34
–1.49
–1.69
–1.76
–0.84
–2.15
–2.59
–2.65
–1.83
–2.28
–2.27
–2.82
–1.43
–1.37
–1.21
2.02
1.67
0.67
1.39
1.17
–1.38
–2.54
–1.05
–1.04
–0.43
P value
0.01a
0.03a
0.02a
0.01a
0.03a
0.03a
0.01a
0.03a
0.25
0.18
0.18
0.14
0.10
0.09
0.42
0.04a
0.01a
0.01a
0.08
0.04a
0.03a
0.01a
0.16
0.19
0.25
0.05
0.10
0.52
0.18
0.27
0.17
0.02a
0.31
0.31
0.68
Notes: all patients took a modified Shenzhuo formula (200 mL, b.d.). Shenzhuo formula was taken 30 min before or after breakfast and
supper. HbA1C: glycosylated hemoglobin; SBP: systolic pressure; DBP: diastolic pressure; TC: total cholesterol; TG: triglycerides; HDL­C:
high­density lipoprotein­cholesterol; LDL­C: low­density lipoprotein­cholesterol. Compared with baseline, aP < 0.05.
Table 4 Variations in indices in patients with DKD after intervention ( xˉ ± s)
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tion. Urinary protein and HbA1C levels were not signifi­
cantly different compared with those at the first visit.
The relationships among kidney damage and glycemia,
BP, and lipids at the first visit is shown in Figure 2. Fi­
nal­visit eGFR was significantly higher among those
with improved/non­worsened kidney function com­
pared with those with worsened kidney function. The
rate of eGFR decrease was significantly lower among
those with non­worsened kidney function compared
with those with worsened kidney function. Patients
with improved/non­worsened kidney function had bet­
ter­controlled urinary protein, HbA1C, and BP (Table
5). The prevalence of uncontrolled blood glucose in pa­
tients with worsened kidney function was higher than
in those with improved/non­worsened kidney func­
tion, whereas the prevalence of uncontrolled lipids and
BP was not significantly different (Table 6).
rScr and relevant indices
The relationships among rScr and percentage change
in urinary protein, glycemia, BP, and lipid profile is
shown in Figure 3. An obvious relationships among rScr
and percentage change in urinary proteinwas observed.
Safety analyses
The liver function and routine blood test of all the par­
ticipants indicated no significant changes after inter­
vention compared with baseline. No severe adverse
events were reported.
DISCUSSION
Reversal of DKD is usually difficult once micro­albu­
minuria has become established. eGFR declines gradu­
ally when overt proteinuria appears. Researchers have
reported decreases in eGFRof 2­10mL/min per 1.73 m2/
y.16­19 In this retrospective study using Shenzhuo formu­
la to treat DKD, mean eGFR increased by 2.11 mL/
min per 1.73 m2/y, and rScr showed a declining trend
(4.71 after 6 months, 10.03 after 12 months). The
treatment could postpone commencement of dialysis
for ≈ 5 years.15 These results suggest that TCM could
provide a new, alternative therapy for DKD.
Our data suggested that the rate of eGFR decrease, lon­
ger course of DKD, younger age at diagnosis, as well as
higher levels of Scr, lipids, and BP at the first visit were
200
190
180
170
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150
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4
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SBP (at first visit)
HBA1C (at first visit)
TC (at first visit)
lineare (SBP at first visit)
lineare (HBA1C at first visit)
lineare (TC at first visit)
­5 0 5 10
GFR drop rate
Figure 2 Relationships among kidney function and glycemia, blood pressure, and lipid profile at the first visit
SBP: systolic blood pressure; HbA1C: glycosylated hemoglobin; TC: total cholesterol.
Figure 1 Relationships among kidney function, age, diabetes mellitus course, and age at diagnosis
DM: diabetes mellitus; DKD: diabetic kidney disease.
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DM diagnostic age
DKD diagnostic age
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related to worsening kidney function. rScr and percent­
age change in urinary protein have been reported to af­
fect the progression of kidney damage.20 Well­con­
trolled levels of glucose and lipids in the blood, as well
Male/female (n)
Duration of
DM [n (%)]
Scr [n (%)]
eGFR [n (%)]
Rate of GFR
decrease
Albuminuria
[n (%)]
HbA1C [n (%)]
TC [n (%)]
SBP [n (%)]
Worsened
baseline
18/6
12.49 (6.34)
197.64
(106.97)
43.12
(15.66)
–0.26
678.01
(820.49)
7.23 (1.50)
6.62 (1.93)
149.76
(24.03)
Follow­up
188.70
(92.79)
41.26
(14.34)
605.61
(909.01)
6.75
(0.77)
5.83
(1.41)
140.47
(14.55)
P value,
(baseline vs
follow­up)
­
­
0.250
0.713
­
0.715
0.320
0.199
0.078
Improved/non­worsened
baseline
42/22
11.61 (8.63)
171.52
(93.00)
41.80
(25.38)
2.37
680.43
(838.32)
7.26
(1.38)
5.89
(1.89)
145.33
(23.05)
Follow­up
149.20
(103.81)
52.58
(20.99)
264.60
(425.13)
6.68 (1.31)
5.99 (1.41)
136.90
(15.97)
baseline vs
follow­up
­
0.656
0.000
0.000
0.000
0.050
0.050
0.815
0.020
P value
Baseline vs
baseline
­
­
0.263
0.598
­
0.991
0.964
0.232
0.501
Follow­up
vs follow­up
­
­
0.106
0.046
­
0.089
0.874
0.740
0.421
Notes: all patients took a modified Shenzhuo formula (200 mL, b.d.). Shenzhuo formula was taken 30 min before or after breakfast and
supper. Worsened: patients whose kidney function worsened; improved/non­worsened: patients whose kidney function improved/did not
worsen; DKD: diabetic kidney disease; DM: diabetes mellitus; Scr: serum creatinine; eGFR: estimated glomerular filtration rate; HbA1C:
glycosylated hemoglobin; TC: total cholesterol; SBP: systolic blood pressure.
Table 5 Analyses of related factors between patients with DKD whose kidney function worsened and those with improved/
non-worsened kidney function after intervention
Treatment outcome
Uncontrolled HbA1C
Uncontrolled blood pressure
Uncontrolled blood cholesterol
Worsen
8 (60.0)
4 (28.6)
10 (44.4)
Improved/not worsened
39 (51.9)
10 (27.8)
30 (46.1)
P value
0.563
0.607
0.619
Table 6 Control of glycosylated hemoglobin, blood pressure, and lipid profile in patients with DKD with worsened and improved/
non-worsened kidney function after intervention [n (%)]
Notes: all patients took a modified Shenzhuo formula (200 mL, b.d.). Shenzhuo formula was taken 30 min before or after breakfast and
supper. Worsened: patients whose kidney function worsened; improved/not worsened: patients whose kidney function improved/did not
worsen; uncontrolled HbA1C: prevalence of uncontrolled glycosylated hemoglobin; uncontrolled blood pressure: prevalence of uncontrolled
blood glucose; uncontrolled blood cholesterol: prevalence of uncontrolled blood cholesterol; DKD: diabetic kidney disease; HbA1C: glycosyl­
ated hemoglobin.
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Figure 3 Relationships among reciprocal serum creatinine and percentage change in albuminuria, glycemia, BP, and lipid profile
SBP: systolic blood pressure; HbA1C: glycosylated hemoglobin; TC: total cholesterol.
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as BP, would benefit kidney function. Our results were
limited by the small study cohort and short follow­up
period, but outcomes similar to ours have been report­
ed.5­7,16­19 Thus, our preliminary findings suggest that
Shenzhuo formula is effective against DKD.
Generation of free radicals is increased, and levels of
free radical­scavenging antioxidant enzymes (e.g., su­
peroxide dismutase) are reduced with the development
of DM. Along with increases in the products of lipid
peroxidation (e.g., malondialdehyde), this results in
kidney tissue damage. Research has shown that Rheum
palmatum can "mop up" various reactive oxygen spe­
cies.21 Huangqi (Radix Astragali Mongolici) and Dansh­
en (Radix Salviae Miltiorrhizae) can increase the activi­
ty of superoxide dismutase, reduce the level of malondi­
aldehyde, inhibit lipid peroxidation, and improve per­
oxide­induced injury in vascular endothelial cells.22,23 A
combination of these two herbs could correct the im­
balance in oxidative stress and eliminate the pathologic
abnormalities of DKD. Shuizhi (Hirudo) can protect
the kidney by lowering the expression of endothe­
lin­1.24 Rhein can reverse the hypertrophy of proximal
tubular epithelial cells induced by transforming growth
factor (TGF)­β1, inhibit the synthesis of the extracellu­
lar matrix stimulated by TGF­β1,25 and postpone PKD
progression. Conversely, abnormalities in the expres­
sion of lipid metabolites participate in PKD progres­
sion.26 Oxidized low­density lipoprotein plays an im­
portant part in this process. Research has shown that
tanshinone can lower expression of the low­density li­
poprotein receptor by inhibiting the signaling pathway
of nuclear factor­kappa B, which can decrease the gen­
eration of macrophage foam cells.27 Dahuang (Radix et
Rhizoma Rhei Palmati) can also improve lipid metabo­
lism disorders.28
In another retrospective study, Shenzhuo formula was
used to treat 63 DKD patients with micro­albumin­
uria.29 Results showed that after intervention for 3
months and 6 months, micro­albuminuria was de­
creased in 92.1% and 90.5% of patients, respectively.
Simultaneously, levels of HbA1C, SBP, and TC were re­
duced significantly.
The present retrospective study showed that Shenzhuo
formula can slow DKD progression and, to a certain
extent, control blood levels of glucose and lipids as well
as BP. Large­scale randomized clinical trials should be
launched to assess the efficacy of Shenzhuo formula
against DKD.
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